{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:26:44Z","timestamp":1793039204423,"version":"4.5.0"},"reference-count":83,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin\u20101 receptor antagonist, is now recommended early in HLH\/MAS, with intravenous (IV) use proposed in critically unwell patients. This systematic review establishes the literature relating to IV anakinra in secondary HLH\/MAS (sHLH\/MAS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened Embase, PubMed, and Medline, including all reports of IV anakinra for HLH or MAS. We extracted age, HLH\/MAS trigger, continuous infusion or bolus dosing, and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010nine case reports\/series identified 87 patients (median age 22\u2009years, range 22\u2009months to 84\u2009years), all with sHLH. Amongst identifiable triggers, 43% were systemic infection, 33% rheumatological, 9% oncological. Children had predominantly a rheumatological trigger (48%), whilst adults were more commonly infection\u2010driven (50%). Overall, rheumatologically triggered disease showed greater survival (83.3%), particularly compared with oncological triggers (42.9%). Children had a greater survival, particularly under 10\u2009years (83%, vs. adults, 63%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite IV anakinra recipients likely to be critically unwell, this cohort had similar disease triggers and survival compared to large historical cohorts, and enhances awareness of age and trigger\u2010specific survival patterns. IV anakinra had a wide therapeutic dosing range and tolerability, regardless of trigger, demonstrating substantial utility in severe sHLH\/MAS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14029","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T19:39:10Z","timestamp":1687549150000},"page":"458-476","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: A systematic review"],"prefix":"10.1111","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-7383","authenticated-orcid":false,"given":"James E. G.","family":"Charlesworth","sequence":"first","affiliation":[{"name":"Department of Paediatrics Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Kavirayani","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00119"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.19150"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061813-012806"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.777851"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005361"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004581"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349"},{"key":"e_1_2_9_13_1","unstructured":"Electronic Medicines Compendium.Kineret 100 mg solution for injection in a pre\u2010filled syringe\u2014summary of product characteristics (SmPC).emc. Accessed June 4 2020.https:\/\/www.medicines.org.uk\/emc\/product\/559"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.024"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00421-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025858"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.01.005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1897"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217706"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102537"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez110.046"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41103"},{"key":"e_1_2_9_24_1","unstructured":"NHS England.Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [210701P] (1924).2021Accessed May 13 2022.https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/10\/1924-Clinical-commissioning-policy-anakinra-for-haemophagocytic-lymphohistiocytosis-.pdf"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470040032"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199707000-00010"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519090"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30361-1"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.002"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.635080"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.103"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600537"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10374"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10369"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11140"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20024"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.02.038"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12002"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.N.00230"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.039"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969\u2010018\u20100265\u20106"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key273.029"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29102"},{"key":"e_1_2_9_45_1","first-page":"292","article-title":"Off\u2010licence use of anakinra in critically ill adults with suspected haemophagocytosis\u2014a single centre experience","volume":"78","author":"Shabbir S","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez108.047"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa040"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.007"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969\u2010020\u201000470\u20105"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11135"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pcc.0000741256.49635.27"},{"key":"e_1_2_9_52_1","article-title":"Delayed marrow engraftment as an atypical presentation of hemophagocytic lymphohistiocytosis","volume":"68","author":"Jones N","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00585-3"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00248-4"},{"key":"e_1_2_9_55_1","article-title":"Mortality and clinical response to treatment in children with secondary hemophagocytic lymphohistiocytosis (SHLH)","volume":"19","author":"Bracaglia C","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"e_1_2_9_56_1","article-title":"Bowel perforation during haemophagocytic lymphohistiocytosis treatment with corticosteroids and anakinra","volume":"8","author":"Adamski J","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/life12020149"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000810380.26200.b7"},{"key":"e_1_2_9_59_1","article-title":"Refractory macrophage activation syndrome secondary to anti\u2010mda5 antibody positive juvenile dermatomyositis","volume":"149","author":"Stewart JA","year":"2022","journal-title":"Pediatrics"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2021-006376"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105524"},{"key":"e_1_2_9_62_1","unstructured":"Office for National Statistics UK NHS Digital.Health Survey for England 2019: Data tables.2020Accessed October 15 2021.https:\/\/files.digital.nhs.uk\/DE\/D1D9C5\/HSE19-Overweight-obesity-tab.xlsx"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000001827"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.03.025"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001791"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30219-8"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30215-0"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100817"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100823"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269065"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7243"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41699"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00377-5"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30556-7"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.022"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.563"},{"key":"e_1_2_9_77_1","article-title":"Adverse effects of biologics: a network meta\u2010analysis and Cochrane overview","volume":"2011","author":"Singh JA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141113"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.624248"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050847"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00074-20"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102537"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11331"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211068840"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:34:59Z","timestamp":1692264899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/ejh.14029"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14029","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"2023-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}